(Q34385556)

25346591

1 August 2017

title

How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis (English)

1 reference

1 August 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25346591%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Monique Kamaria

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25346591%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

J Y Koo

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25346591%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

1 January 2010

1 reference

1 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25346591%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25346591%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25346591%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

36-42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25346591%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205949

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205949

Relapse, rebound, and psoriasis adverse events: an advisory group report.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205949

Update on the mechanisms and efficacy of biological therapies for psoriasis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205949

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205949

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205949

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205949

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4205949

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

27 October 2018

1 reference

12 December 2020

Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study

1 reference

12 December 2020

Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy

1 reference

12 December 2020

Definitions of Measures of Effect Duration for Psoriasis Treatments

1 reference

12 December 2020

Remittive effects of intramuscular alefacept in psoriasis

1 reference

12 December 2020

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25346591%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

25346591

1 reference